News

HannaH, an open-label trial involving 596 women compared Herceptin given as subcutaneous (SC) injection versus that given as an intravenous (IV) infusion. Herceptin SC uses Enhanze Technology which

Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells which help in immunity, as well as kinases that play key roles in various cancers. The

The new Aclar UltRx 6000 is part of the Aclar family of films, protects moisture-sensitive medicines in all climates and allows pharmaceutical companies to standardise their product packaging.

The discovery partnership spans for an initial period of 3 years, under which Norgine will be provided with a platform to develop multiple targets utilising Jubilant’s integrated drug

Previously, Hari Kumar served as chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira’s fibrosis program. According to the

UshStat was developed using LentiVector platform technology, which is a gene delivery system, with applications in product development and discovery research. The open label, dose escalation Phase I/IIa

Lazanda uses the company’s PecSys drug delivery system, which helps in the rapid absorption of the ingredient across the nasal membrane and directly into the blood stream. The

MultiStem, administered intravenously, is an allogeneic cell therapy product candidate which helps promote healing and tissue repair. The Phase I multi-center dose escalation clinical trial is intended to

The additional studies extended earlier data where BT2111, a conjugate made up of biOasis Transcend vector and trastuzumab (Herceptin), a humanized monoclonal antibody, demonstrated increased ability to kill